Mymd Pharmaceuticals (NASDAQ:QCLS) Shares Up 5.4% – Here’s What Happened

Mymd Pharmaceuticals, Inc. (NASDAQ:QCLS) shares traded up 5.4% on Monday . The company traded as high as $2.81 and last traded at $2.75. Approximately 75,025 shares were traded during trading, a decline of 61% from the average daily volume of 190,927 shares. The stock had previously closed at $2.61.

Analysts Set New Price Targets

A number of equities research analysts have issued reports on the company. Wall Street Zen upgraded Mymd Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Saturday, May 23rd. Weiss Ratings began coverage on Mymd Pharmaceuticals in a research report on Wednesday, May 13th. They issued a “sell (e+)” rating on the stock. One analyst has rated the stock with a Sell rating, According to data from MarketBeat, the stock has an average rating of “Sell”.

Mymd Pharmaceuticals Price Performance

The business’s fifty day moving average is $3.63. The company has a market capitalization of $12.30 million, a price-to-earnings ratio of -0.14 and a beta of 2.16.

Mymd Pharmaceuticals (NASDAQ:QCLS) last released its earnings results on Friday, May 15th. The company reported ($0.19) EPS for the quarter.

Mymd Pharmaceuticals Company Profile

MyMD Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on developing novel therapies for immune-related and other serious diseases. The company has worked on product candidates designed to address conditions involving inflammation, immune system dysfunction, and age-related disease processes.

The company’s pipeline has included drug development programs in areas such as autoimmune and inflammatory disorders, with an emphasis on advancing compounds through preclinical and clinical evaluation.